Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.68 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10349992 | 1.00 | HRH1 (0.68) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL17259193 | 1.00 | HRH1 (0.68) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL5545817 | 1.00 | HRH1 (0.68) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL742488 | 1.00 | HRH1 (0.68) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL5543830 | 1.00 | HRH1 (0.68) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL1288240 | 0.98 | TDP1 (0.67) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL294520 | 0.92 | CYP2A6 (0.66) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL29485634 | 0.90 | HRH1 (0.81) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL2845851 | 0.90 | HRH1 (0.81) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL29485667 | 0.90 | HRH1 (0.81) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140595-A1 | TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118255685-A | Tricyclic compound, pharmaceutical composition and application thereof | 珂阑(上海)医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-05-17 | — | — | US | disclosed |
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-05-17 | — | — | US | disclosed |
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2012-05-17 | — | — | US | disclosed |
| EP-2430074-A1 | DI-SUBSTITUTED PYRIDINIUM POLYMERS AND SYNTHESIS THEREOF | University Court Of The University Of Aberdeen (GB) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010086652-A1 | DI-SUBSTITUTED PYRIDINIUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086652-A1 | DI-SUBSTITUTED PYRIDINIUM POLYMERS AND SYNTHESIS THEREOF | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-08-05 | — | — | WO | disclosed |
| EP-0619807-A1 | NEW BHT ETHER COMPOUNDS AND THEIR USE AS HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC DRUGS | MERTZ + CO., GMBH & CO (DE) | 1994-10-19 | — | — | EP | disclosed |
| US-5254549-A | New BHT ether compounds and their use as hypolipidemic and antiatherosclerotic drugs | MERZ & CO. GMBH & CO. (DE) | 1993-10-19 | — | — | US | disclosed |
| WO-1993012089-A1 | NEW BHT ETHER COMPOUNDS AND THEIR USE AS HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC DRUGS | MERZ + CO., GMBH & CO. (DE) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123113-A1 | DI-SUBSTITUTED PYRIDINUM POLYMERS AND SYNTHESIS THEREOF | PDXK, RAD54L, CDKL5 | HRH1 281/4885TBXAS1 1119/4885TDP1 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.